不同剂量人血丙种球蛋白辅助治疗重症手足口病的临床效果

Clinical efficacy of different doses IVIG in treatment of severe hand, foot and mouth disease

目的 比较不同剂量人血丙种球蛋白辅助治疗重症手足口病患儿的临床疗效。方法 选择2011年6月～2014年9月我院手足口病患儿80例为研究对象,随机分为4组,每组20例。所有患者均给予抗常规治疗治疗。第1组、第2组和第3组在此基础上加用人血病种球带白治疗,第1组剂量1g/（kg·d）,第2组0.5g/（kg·d）,第3组0.2g/（kg·d）,第4组不加用人血病种球带白治疗。观察4组患者的临床疗效。结果 第1组、第2组以及第3组发热缓解时间、治愈时间均显著早于第4组（P〈0.05）,而第1、2、3组间比较差异无统计学意义（P〉0.05）;第1组住院费用最高,显著高于第2、3、4组（P〈0.05或P〈0.01）。结论 丙种球蛋白辅助治疗重症手足口病能够显著提高临床治疗效果,而低剂量与中高剂量丙种球蛋白具有相似的临床效果。

Objective To discuss clinical efficacy of different doses IVIG in treatment of children with severe hand, foot and mouth disease. Methods Selected 80 cases with severe hand, foot and mouth disease were randomly divided into four groups. All cases were treated by conventional treatment. Group l, group 2 and group 3 were treated by IVIG based on conventional treatment, with doses of lg/（kg · d）, 0.Sg/（kg · d） and 0.2g/（kg · d）. Group 4 was not treated by IVIG. Clinical efficacy of 4 groups was compared. Results Fever relief time, cure time of group 1, group 2 and group 3 were shorter than group 4（P 〈 0.05）, and those compared in group 1, group 2 and group 3 showed no significant difference（P 〉 0.05）; Hospital costs of group 1 was highest, which was higher than group 2, group 3 and group 4 （P 〈 0.05 or P 〈 0.01）. Conclusion IVIG in treatment of children with severe hand, foot and mouth disease can improve clinical efficacy, and Low-dose and moderate and shigh-dose gamma IVIG have similar clinical effects.